Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCO

Affiliation auteurs!!!! Error affiliation !!!!
TitreInduction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCO
Type de publicationJournal Article
Year of Publication2018
AuteursYchou M, Rivoire M, Thezenas S, Guimbaud R, Ghiringhelli F, Blas AMercier, Mineur L, Francois E, Khemissa F, Chauvenet M, Becouarn Y, Houyau P, Aparicio T, Galais MPierre, Audemar F, Assenat E, Adenis A, Jouffroy-Zeller C, Adam R, Bouche O
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume36
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2018.36.15_suppl.3535